SEC Form 4 · accession 0001012975-17-000722
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sybil Tasker
Officer — Chief Medical Officer
Period of report
Sep 22, 2017
Accepted (ET)
Sep 26, 2017 · 6:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (option to buy)F1 | $2.48 | Sep 22, 2017 | A | 50,000 | A | — | Sep 22, 2027 | Common Stock, par value $0.0001 | 50,000 | 50,000 | D |
Explanation of responses
- F1On the first anniversary of the date of grant, 25% of the unvested portion of the option will become vested and exercisable, and the aggregate remaining unvested portion will vest and become exercisable in equal monthly installments over the 36-month period following such anniversary date.